Molecular mechanism of microRNAs, long noncoding RNAs, and circular RNAs regulating lymphatic metastasis of bladder cancer
Urol Oncol. 2023 Nov 20:S1078-1439(23)00351-4. doi: 10.1016/j.urolonc.2023.10.012. Online ahead of print.ABSTRACTBladder cancer (BC), a malignancy originating in the epithelial tissue in the inner wall of the bladder, is a common urological cancer type. BC spreads through 3 main pathways: direct infiltration, lymphatic metastasis, and hematogenous metastasis. Lymphatic metastasis is considered a poor prognostic factor for BC and is often associated with lower survival rates. The treatment of BC after lymphatic metastasis is complex and challenging. A deeper understanding of the molecular mechanisms underlying lymphatic met...
Source: Urologic Oncology - November 21, 2023 Category: Urology & Nephrology Authors: Wei Zengzhao Lan Xuan Ma Xiaohan Hou Encun Chen Jibing Gao Hongjun Source Type: research
Oncologic outcomes of patients treated with kidney-sparing surgery or radical nephroureterectomy for upper urinary tract urothelial cancer: a population-based study
CONCLUSION: In this population-based study, SU provides equivalent CSS and OS compared to RNU, even in high-risk and locally advanced ureteral cancer. Due to the unavoidable risk of selection bias, further prospective studies are expected to overcome the limitations of this study and support the wider implementation of KSS.PMID:37981503 | DOI:10.1016/j.urolonc.2023.09.019 (Source: Urologic Oncology)
Source: Urologic Oncology - November 19, 2023 Category: Urology & Nephrology Authors: Aleksander Ślusarczyk Piotr Zapa ła Łukasz Zapała Pawe ł Rajwa Marco Moschini Ekaterina Laukhtina Piotr Radziszewski Source Type: research
Oncologic outcomes of patients treated with kidney-sparing surgery or radical nephroureterectomy for upper urinary tract urothelial cancer: a population-based study
CONCLUSION: In this population-based study, SU provides equivalent CSS and OS compared to RNU, even in high-risk and locally advanced ureteral cancer. Due to the unavoidable risk of selection bias, further prospective studies are expected to overcome the limitations of this study and support the wider implementation of KSS.PMID:37981503 | DOI:10.1016/j.urolonc.2023.09.019 (Source: Urologic Oncology)
Source: Urologic Oncology - November 19, 2023 Category: Urology & Nephrology Authors: Aleksander Ślusarczyk Piotr Zapa ła Łukasz Zapała Pawe ł Rajwa Marco Moschini Ekaterina Laukhtina Piotr Radziszewski Source Type: research
Anticoagulation prophylaxis patterns following retroperitoneal lymph node dissection for testis cancer
CONCLUSIONS: AC appears beneficial with minimal risk of harm after RPLND, especially in patients with higher risk of developing DVT/PE, highlighting the safety and efficacy of this regimen. There was a significant increase in the rate of AC prophylaxis at discharge amongst patients undergoing RPLND in the institutional database from 2013 to 2022. A risk-stratified protocol of postoperative AC following RPLND appears reasonable, and further prospective trials are warranted to formally confirm this recommendation.PMID:37980224 | DOI:10.1016/j.urolonc.2023.10.009 (Source: Urologic Oncology)
Source: Urologic Oncology - November 18, 2023 Category: Urology & Nephrology Authors: Vincent D'Andrea Zhiyu Jason Qian Kendrick Yim Jillian Egan Christopher J Magnani Adam Feldman Keyan Salari Alok Tewari Graeme Steele Matthew Mossanen Mark Preston Steven L Chang Timothy N Clinton Source Type: research
Anticoagulation prophylaxis patterns following retroperitoneal lymph node dissection for testis cancer
CONCLUSIONS: AC appears beneficial with minimal risk of harm after RPLND, especially in patients with higher risk of developing DVT/PE, highlighting the safety and efficacy of this regimen. There was a significant increase in the rate of AC prophylaxis at discharge amongst patients undergoing RPLND in the institutional database from 2013 to 2022. A risk-stratified protocol of postoperative AC following RPLND appears reasonable, and further prospective trials are warranted to formally confirm this recommendation.PMID:37980224 | DOI:10.1016/j.urolonc.2023.10.009 (Source: Urologic Oncology)
Source: Urologic Oncology - November 18, 2023 Category: Urology & Nephrology Authors: Vincent D'Andrea Zhiyu Jason Qian Kendrick Yim Jillian Egan Christopher J Magnani Adam Feldman Keyan Salari Alok Tewari Graeme Steele Matthew Mossanen Mark Preston Steven L Chang Timothy N Clinton Source Type: research
A brief mind-body intervention to reduce pain and anxiety during prostate needle biopsy: a clinically integrated randomized controlled trial with 2-staged consent
CONCLUSIONS: A clinically meaningful benefit for this brief mind-body intervention during prostate biopsy is unlikely. Robust patient enrollment is feasible using 2-stage consent.PMID:37977915 | DOI:10.1016/j.urolonc.2023.09.016 (Source: Urologic Oncology)
Source: Urologic Oncology - November 17, 2023 Category: Urology & Nephrology Authors: Christopher D Gaffney Emily A Vertosick Sigrid V Carlsson Xin Lin Natalie Wolchasty Robin Hardbattle Andrew J Vickers Behfar Ehdaie Source Type: research
A systematic review of pN0 testicular seminoma: a new clinical entity and future directions
Urol Oncol. 2023 Nov 13:S1078-1439(23)00343-5. doi: 10.1016/j.urolonc.2023.10.008. Online ahead of print.ABSTRACTRetroperitoneal lymph node dissection (RPLND) for testicular seminoma with enlarged retroperitoneal lymph nodes has received increased consideration and exposed a new clinical entity: pN0 disease. Enlarged, nonmetastatic retroperitoneal lymph nodes provide insight into the natural history of seminoma while offering a benchmark for improving the accuracy of staging. The purpose of this systematic review was to report the pN0 rates, describe risk factors associated with it, and discuss emerging research that may r...
Source: Urologic Oncology - November 15, 2023 Category: Urology & Nephrology Authors: Ala'a Farkouh Kanha Shete Kai Wen Cheng Matthew I Buell Brian Hu Source Type: research
Re: Multiparametric MRI is not sufficient for prostate cancer staging: A single institutional experience validated by a multi-institutional regional collaborative. Thenappan Chandrasekar, Andrew Denisenko, Vasil Mico and Colleagues. Urological Oncology: Seminars and Original Investigations 41 (2023) 355.e1-355.e8
Urol Oncol. 2023 Nov 13:S1078-1439(23)00293-4. doi: 10.1016/j.urolonc.2023.08.018. Online ahead of print.NO ABSTRACTPMID:37968168 | DOI:10.1016/j.urolonc.2023.08.018 (Source: Urologic Oncology)
Source: Urologic Oncology - November 15, 2023 Category: Urology & Nephrology Authors: Eoin Dinneen Veeru Kasivisvanathan Francesco Giganti Clare Allen Greg Shaw Shonit Punwani Source Type: research
Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition
Urol Oncol. 2023 Nov 13:S1078-1439(23)00342-3. doi: 10.1016/j.urolonc.2023.10.004. Online ahead of print.ABSTRACTTransurethral resection of bladder tumor followed by intravesical Bacillus Calmette-Guérin (BCG) is the standard of care in high-risk, non-muscle-invasive bladder cancer (NMIBC). Although many patients respond, recurrence and progression are common. In addition, patients may be unable to receive induction + maintenance due to intolerance or supply issues. Therefore, alternative treatment options are urgently required. Programmed cell death (ligand) 1 (PD-[L]1) inhibitors show clinical benefit in phase 1/2 trial...
Source: Urologic Oncology - November 15, 2023 Category: Urology & Nephrology Authors: Jens Bedke Peter C Black Bernadett Szabados F élix Guerrero-Ramos Shahrokh Fran çois Shariat Evanguelos Xylinas Julia Brinkmann John A Blake-Haskins Rossano Cesari Joan Palou Redorta Source Type: research
A systematic review of pN0 testicular seminoma: a new clinical entity and future directions
Urol Oncol. 2023 Nov 13:S1078-1439(23)00343-5. doi: 10.1016/j.urolonc.2023.10.008. Online ahead of print.ABSTRACTRetroperitoneal lymph node dissection (RPLND) for testicular seminoma with enlarged retroperitoneal lymph nodes has received increased consideration and exposed a new clinical entity: pN0 disease. Enlarged, nonmetastatic retroperitoneal lymph nodes provide insight into the natural history of seminoma while offering a benchmark for improving the accuracy of staging. The purpose of this systematic review was to report the pN0 rates, describe risk factors associated with it, and discuss emerging research that may r...
Source: Urologic Oncology - November 15, 2023 Category: Urology & Nephrology Authors: Ala'a Farkouh Kanha Shete Kai Wen Cheng Matthew I Buell Brian Hu Source Type: research
Re: Multiparametric MRI is not sufficient for prostate cancer staging: A single institutional experience validated by a multi-institutional regional collaborative. Thenappan Chandrasekar, Andrew Denisenko, Vasil Mico and Colleagues. Urological Oncology: Seminars and Original Investigations 41 (2023) 355.e1-355.e8
Urol Oncol. 2023 Nov 13:S1078-1439(23)00293-4. doi: 10.1016/j.urolonc.2023.08.018. Online ahead of print.NO ABSTRACTPMID:37968168 | DOI:10.1016/j.urolonc.2023.08.018 (Source: Urologic Oncology)
Source: Urologic Oncology - November 15, 2023 Category: Urology & Nephrology Authors: Eoin Dinneen Veeru Kasivisvanathan Francesco Giganti Clare Allen Greg Shaw Shonit Punwani Source Type: research
Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition
Urol Oncol. 2023 Nov 13:S1078-1439(23)00342-3. doi: 10.1016/j.urolonc.2023.10.004. Online ahead of print.ABSTRACTTransurethral resection of bladder tumor followed by intravesical Bacillus Calmette-Guérin (BCG) is the standard of care in high-risk, non-muscle-invasive bladder cancer (NMIBC). Although many patients respond, recurrence and progression are common. In addition, patients may be unable to receive induction + maintenance due to intolerance or supply issues. Therefore, alternative treatment options are urgently required. Programmed cell death (ligand) 1 (PD-[L]1) inhibitors show clinical benefit in phase 1/2 trial...
Source: Urologic Oncology - November 15, 2023 Category: Urology & Nephrology Authors: Jens Bedke Peter C Black Bernadett Szabados F élix Guerrero-Ramos Shahrokh Fran çois Shariat Evanguelos Xylinas Julia Brinkmann John A Blake-Haskins Rossano Cesari Joan Palou Redorta Source Type: research
A systematic review of pN0 testicular seminoma: a new clinical entity and future directions
Urol Oncol. 2023 Nov 13:S1078-1439(23)00343-5. doi: 10.1016/j.urolonc.2023.10.008. Online ahead of print.ABSTRACTRetroperitoneal lymph node dissection (RPLND) for testicular seminoma with enlarged retroperitoneal lymph nodes has received increased consideration and exposed a new clinical entity: pN0 disease. Enlarged, nonmetastatic retroperitoneal lymph nodes provide insight into the natural history of seminoma while offering a benchmark for improving the accuracy of staging. The purpose of this systematic review was to report the pN0 rates, describe risk factors associated with it, and discuss emerging research that may r...
Source: Urologic Oncology - November 15, 2023 Category: Urology & Nephrology Authors: Ala'a Farkouh Kanha Shete Kai Wen Cheng Matthew I Buell Brian Hu Source Type: research
Re: Multiparametric MRI is not sufficient for prostate cancer staging: A single institutional experience validated by a multi-institutional regional collaborative. Thenappan Chandrasekar, Andrew Denisenko, Vasil Mico and Colleagues. Urological Oncology: Seminars and Original Investigations 41 (2023) 355.e1-355.e8
Urol Oncol. 2023 Nov 13:S1078-1439(23)00293-4. doi: 10.1016/j.urolonc.2023.08.018. Online ahead of print.NO ABSTRACTPMID:37968168 | DOI:10.1016/j.urolonc.2023.08.018 (Source: Urologic Oncology)
Source: Urologic Oncology - November 15, 2023 Category: Urology & Nephrology Authors: Eoin Dinneen Veeru Kasivisvanathan Francesco Giganti Clare Allen Greg Shaw Shonit Punwani Source Type: research
Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition
Urol Oncol. 2023 Nov 13:S1078-1439(23)00342-3. doi: 10.1016/j.urolonc.2023.10.004. Online ahead of print.ABSTRACTTransurethral resection of bladder tumor followed by intravesical Bacillus Calmette-Guérin (BCG) is the standard of care in high-risk, non-muscle-invasive bladder cancer (NMIBC). Although many patients respond, recurrence and progression are common. In addition, patients may be unable to receive induction + maintenance due to intolerance or supply issues. Therefore, alternative treatment options are urgently required. Programmed cell death (ligand) 1 (PD-[L]1) inhibitors show clinical benefit in phase 1/2 trial...
Source: Urologic Oncology - November 15, 2023 Category: Urology & Nephrology Authors: Jens Bedke Peter C Black Bernadett Szabados F élix Guerrero-Ramos Shahrokh Fran çois Shariat Evanguelos Xylinas Julia Brinkmann John A Blake-Haskins Rossano Cesari Joan Palou Redorta Source Type: research
